OncoMatch/Clinical Trials/NCT06193759
Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT)
Is NCT06193759 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Multi-tumor antigen specific cytotoxic T lymphocytes (TSA-T) directed against proteogenomically determined personalized tumor-specific antigens (TSA) and Group A Standard-of-Care Backbone Therapy for medulloblastoma, childhood.
Treatment: Multi-tumor antigen specific cytotoxic T lymphocytes (TSA-T) directed against proteogenomically determined personalized tumor-specific antigens (TSA) · Group A Standard-of-Care Backbone Therapy — This is an open-label phase 1 safety and feasibility study that will employ multi-tumor antigen specific cytotoxic T lymphocytes (TSA-T) directed against proteogenomically determined personalized tumor-specific antigens (TSA) derived from a patient's primary brain tumor tissues. Young patients with embryonal central nervous system (CNS) malignancies typically are unable to receive irradiation due to significant adverse effects and are treated with intensive chemotherapy followed by autologous stem cell rescue; however, despite intensive therapy, many of these patients relapse. In this study, individualized TSA-T cells will be generated against proteogenomically determined tumor-specific antigens after standard of care treatment in children less than 5 years of age with embryonal brain tumors. Correlative biological studies will measure clinical anti-tumor, immunological and biomarker effects.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Prior therapy
Cannot have received: immunotherapy with an investigational agent
Prior immunotherapy with an investigational agent within the 28 days prior to planned date of procurement collection for TSA-T manufacturing.
Cannot have received: ATG, Campath or other immunosuppressive T cell monoclonal antibodies (ATG, Campath)
Patients who received ATG, Campath or other immunosuppressive T cell monoclonal antibodies within 28 days of TSA-T infusion.
Lab requirements
Blood counts
ANC 750/1L; ALC >500/1L; Platelets 75K
Kidney function
Serum creatinine 1.0 mg/dL or 1.5x ULN for age (whichever is higher)
Liver function
Bilirubin 3x ULN; AST and ALT <5x ULN
Adequate organ function, defined below: i. ANC 750/1L. ii. Absolute lymphocyte count (ALC) >500/1L. iii. Platelets 75K. iv. Bilirubin 3xULN. v. AST and ALT <5x ULN. vi. Serum creatinine 1.0 mg/dL or 1.5x ULN for age (whichever is higher). vii. Pulse oximetry >90% on room air.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Children's National Hospital · Washington D.C., District of Columbia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify